USPTO serial 88108803
CYCLERION
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RUTLAND, BARBARA A
- Law office
- DIVISIONAL UNIT
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CYCLERION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, preparations that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 17, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 17, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 8, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 7, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 31, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 31, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 2, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 28, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 28, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 16, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 14, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 14, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 14, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 8, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 8, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 8, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 19, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 15, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 15, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 14, 2020 | NOAC | CORRECTED NOA E-MAILED | — |
| May 13, 2020 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| May 12, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 26, 2020 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Apr 26, 2020 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Mar 17, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 16, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 16, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 16, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 16, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 16, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 9, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 9, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 9, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 25, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 25, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 25, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jun 19, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 20, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 20, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 20, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 17, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 11, 2018 | NWAP | NEW APPLICATION ENTERED | — |